Anti-RAET1E antibody [79/6/13/16] (ab95202)
Key features and details
- Mouse monoclonal [79/6/13/16] to RAET1E
- Suitable for: ELISA, IP, ICC/IF, Neutralising, Flow Cyt, WB
- Reacts with: Human
- Isotype: IgG2a
Overview
-
Product name
Anti-RAET1E antibody [79/6/13/16]
See all RAET1E primary antibodies -
Description
Mouse monoclonal [79/6/13/16] to RAET1E -
Host species
Mouse -
Tested applications
Suitable for: ELISA, IP, ICC/IF, Neutralising, Flow Cyt, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment corresponding to Human RAET1E aa 33-227 (N terminal).
-
Positive control
- Stable RAET1E cell line
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituent: 99.98% PBS -
Concentration information loading...
-
Purity
Protein A/G purified -
Clonality
Monoclonal -
Clone number
79/6/13/16 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab95202 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
IP |
Use at an assay dependent concentration.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
|
Neutralising |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use at an assay dependent concentration.
ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
|
WB |
Use at an assay dependent concentration.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
Neutralising
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
WB
Use at an assay dependent concentration. |
Target
-
Function
Ligand for the NKG2D receptor. Delivers activating signals to NK cells and promotes tumor immune surveillance by inducing the expansion of anti-tumor cytotoxic lymphocytes. -
Tissue specificity
Predominantly expressed in the skin, but also expressed in testis and trachea. Up-regulated in tumor cells of different origins. Expression progressively decreased after treatment of tumor cells with retinoic acid. -
Sequence similarities
Belongs to the MHC class I family. -
Cellular localization
Secreted and Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 135250 Human
- Omim: 609243 Human
- SwissProt: Q8TD07 Human
- Unigene: 511818 Human
-
Alternative names
- bA350J20.7 antibody
- LETAL antibody
- Lymphocyte effector toxicity activation ligand antibody
see all
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab95202 has been referenced in 4 publications.
- Hernández C et al. Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4. Helicobacter 26:e12812 (2021). PubMed: 33928707
- Song M et al. Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response. Oncoimmunology 9:1746148 (2020). PubMed: 32363114
- Chitadze G et al. In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. Oncoimmunology 6:e1358839 (2017). PubMed: 29147621
- Mimura K et al. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer 135:1390-8 (2014). PubMed: 24615495